JAZZ
Jazz PublicCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Primary sources support a credible medium-term growth setup: Q1 revenue grew 19%, guidance was reaffirmed, Xywav and Epidiolex remained strong, Modeyso is ramping, and zanidatamab has a dated August 25, 2026 FDA catalyst [#IR-2026-05-05] [#IR-2026-04-27].
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.3.
What can break
Balance-sheet leverage remains meaningful, with $5.4 billion of long-term debt against $2.9 billion of cash, cash equivalents and investments as of March 31, 2026 [#IR-2026-05-05].
Momentum
45
Value
63
Sentiment
36
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $220.00 · Bull $255.00 · Bear $185.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $265.21
Why
Momentum45 · Δ7d -15.2
Value63 · Δ7d -0.3
Sentiment36 · Δ7d -4.1
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
45
26% active weight
Current posture
7d trendFlat
Δ7d
-15.2
Δ21d
-31.2
Value
63
39% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-0.2
Sentiment
36
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.1
Δ21d
-8.3
Why this grade
Composite grade C. Momentum 45.1 / Value 63.3 / Sentiment 35.7
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$15.55B
Beta
0.26
Shares Out
62.82M
P/E (TTM) · Derived
-42.4
P/S (TTM)
2.55
P/FCF (TTM)
8.55
Rev YoY
+19.1%
EPS YoY
-392.2%
Gross Margin
+72.8%
Op Margin
-11.9%
Net Debt
$2.99B
Current Ratio
2.04
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology